New drug for Alzheimer’s disease shows promise in phase 3 trial
Sep 28, 2022
Lecanemab is a monoclonal antibody drug designed to target and help remove Alzheimer’s-associated amyloid plaques in the brain.
More news for Tuesday, Sept. 13
By
Kimberly Bonvissuto
Sep 13, 2022
Senate Aging Committee members seek information on alleged Alzheimer’s research fraud … 14 state governors launch healthcare workforce collaborative … CMS: Free updated COVID-19 vaccines provide...
More news for Friday, July 22
By
Kimberly Bonvissuto
Jul 22, 2022
New division within HHS will lead pandemic response … $250,000 Alzheimer’s Foundation grant will fund research into potential new medications … TX providers encouraged to update emergency plans amid...
Life plan community to provide dementia de-escalation training, simulations
By
Kimberly Bonvissuto
Jul 05, 2022
A Virginia life plan community will use a local grant to train emergency responders and older adult service providers on dementia behavior de-escalation practices, while also exposing their staff to what...
A retirement community desk clerk’s perspective on dementia
By
Kimberly Hollifield
Jul 05, 2022
As a desk clerk in a retirement community, I observed many residents living with dementia. This experience made a big impression on me.
Senior living workforce, affordable housing priorities included in House appropriations proposal
By
Kimberly Bonvissuto
Jul 01, 2022
Workforce development, dementia care and affordable senior housing are among the funding priorities affecting senior living included in the proposed House appropriations bill.
Research focuses on diagnosing, lessening effects of Alzheimer’s disease
By
Kimberly Bonvissuto
Jun 28, 2022
More than 6 million Americans are living with Alzheimer’s disease, costing the nation $321 billion in 2022, according to the Alzheimer’s Association. A variety of studies and pilot programs are underway...
Memory care, falls prevention studies secure nearly $35 million in grant funding
By
Kimberly Bonvissuto
May 31, 2022
Researchers have secured close to a total of $35 million across multiple U.S. studies to identify falls prevention strategies and risk factors for cognitive decline, as well as expand a dementia-specific...
FDA OKs marketing of new test to help diagnose Alzheimer disease
May 06, 2022
The test is indicated for patients 55 years and older who present with cognitive impairment and are being evaluated for Alzheimer’s disease and cognitive decline.
Artificial intelligence, MRI combination achieves 94% accuracy in predicting dementia
By
Kimberly Bonvissuto
Dec 09, 2021
A form of artificial intelligence combined with MRI scans of the brain predicted with 94% accuracy whether individuals with a specific type of early memory loss would go on to develop Alzheimer’s diseases...